XE
XEJ.F Accuray Incorporated
- Market cap
- EUR 316K
- P/E
- -
- P/B
- 0.27x
- ROE
- 76.3%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 1 quarter up to Sep 2026.
Is XEJ.F undervalued?
Graham numberThe Graham number of Accuray Incorporated cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Accuray Incorporated fundamental analysis
No fundamental analysis for Accuray Incorporated yet.
Accuray Incorporated stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Accuray Incorporated
Accuray Incorporated engages in the design, development, and sale of radiosurgery and radiation therapy systems for the treatment of tumors throughout the body in the United States, Canada, Latin America, Australia, New Zealand, Europe, the Middle East, India, Africa, Japan, and China. The company offers the CyberKnife platform, a robotic stereotactic radiosurgery and stereotactic body radiation therapy system used for the treatment of primary and metastatic tumors outside t…
Full company profileAccuray Incorporated financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 1 quarter up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Accuray Incorporated annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 383M | 405M | 419M | 383M | 396M | 430M | 448M | 447M | 459M | 402M | 346M |
| Gross Profit | 141M | 162M | 163M | 150M | 160M | 160M | 154M | 143M | 147M | 111M | 104M |
| Operating Income | -9.82M | -3.80M | 583K | 12.5M | 22.2M | 8.15M | 2.38M | 504K | 7.84M | -10.3M | -2.91M |
| EBITDA | 6.80M | 1.67M | 11.2M | 31.3M | - | - | 8.37M | 5.71M | 20.2M | -6.40M | 98.0M |
| Net Income | -29.6M | -23.9M | -16.4M | 3.83M | -6.31M | -5.35M | -9.28M | -15.5M | -1.59M | -49.2M | 40.5M |
| EPS | -0.35 | -0.28 | -0.19 | 0.04 | -0.07 | -0.06 | -0.10 | -0.16 | -0.02 | -0.41 | 14 |
| Balance Sheet | |||||||||||
| Total Assets | 406M | 379M | 438M | 491M | 480M | 473M | 479M | 469M | 470M | 444M | 390M |
| Total Liabilities | 360M | 330M | 388M | 427M | 411M | 420M | 426M | 424M | 389M | 402M | 337M |
| Shareholders' Equity | 46.5M | 48.6M | 49.9M | 63.6M | 68.8M | 53.2M | 53.7M | 45.1M | 81.2M | 41.7M | 53.1M |
| Cash & Short-term Investments | 72.1M | 83.1M | 76.8M | 108M | 116M | 88.7M | 89.4M | 68.6M | 57.4M | 40.6M | 42.3M |
| Cash Flow | |||||||||||
| Operating Cash Flow | -380K | 18.3M | -29.6M | -1.47M | 38.5M | -2.40M | 15.5M | -11.9M | 2.86M | -6.98M | -15.2M |
| Capital Expenditure | 5.03M | 6.28M | 4.31M | 3.56M | 2.32M | 4.72M | 12.6M | 3.60M | 8.52M | 12.3M | 20.0M |
| Free Cash Flow | -5.74M | 11.7M | -34.0M | -5.20M | 36.2M | -7.12M | 2.86M | -15.5M | -5.66M | -19.3M | -35.3M |
| Ratios | |||||||||||
| ROE | -63.6% | -49.1% | -32.9% | 6.0% | -9.2% | -10.1% | -17.3% | -34.5% | -2.0% | -118.0% | 76.3% |
| ROA | -7.3% | -6.3% | -3.7% | 0.8% | -1.3% | -1.1% | -1.9% | -3.3% | -0.3% | -11.1% | 10.4% |
| Net Profit Margin | -7.7% | -5.9% | -3.9% | 1.0% | -1.6% | -1.2% | -2.1% | -3.5% | -0.3% | -12.2% | 11.7% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Accuray Incorporated dividends
Accuray Incorporated has not paid dividends in the last 9 fiscal years.
Last stock split: 1:40 on Nov 9, 2026.
Who owns Accuray Incorporated
- Insiders 4.62%
- Institutions 64.48%
- Public & others 30.90%
- Shares outstanding 3.00M
- Free float 3.28M
Accuray Incorporated company profile
- Company name
- Accuray Incorporated
- Ticker
- XEJ.F
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Health Care Equipment & Supplies
- Employees
- 809
- Fiscal year end
- June
- Address
- 1240 Deming Way, Madison, WI, United States, 53717-1954
- Phone
- 608 824 2800
- Website
- accuray.com
About Accuray Incorporated
Accuray Incorporated engages in the design, development, and sale of radiosurgery and radiation therapy systems for the treatment of tumors throughout the body in the United States, Canada, Latin America, Australia, New Zealand, Europe, the Middle East, India, Africa, Japan, and China. The company offers the CyberKnife platform, a robotic stereotactic radiosurgery and stereotactic body radiation therapy system used for the treatment of primary and metastatic tumors outside the brain, including tumors on or near the spine and in the breast, kidney, liver, lung, pancreas, and prostate. It also provides the TomoTherapy platform, including the Radixact System, a tailored helical solution, which integrates radiation treatment planning, delivery, imaging, and data management; iDMS data management system, a fully integrated treatment planning and data management systems; and Accuray precision treatment planning system, a treatment planning and data management systems. In addition, the company offers post-contract customer support, installation, training, and other professional services. It primarily markets its products directly to customers, including hospitals and stand-alone treatment facilities through its sales organization, as well as to customers through sales agents and group purchasing organizations in the United States; and to customers directly and through distributors and sales agents internationally. Accuray Incorporated was incorporated in 1990 and is headquartered in Madison, Wisconsin.
Accuray Incorporated management
10- Mr. Stephen R. LaNeve MBAPresident, CEO & Director · born 1959
- Mr. Ali PervaizSenior VP & CFO · born 1980
- Mr. Paul MieleSenior VP & Chief Commercial Officer · born 1982
- Mr. Michael J. Murphy CPACorporate Controller & Principal Accounting Officer · born 1979
- Mr. David ShinSenior VP, Chief Legal Officer & Corporate Secretary
- Dr. Seth Blacksburg M.B.A., M.D.Senior VP and Chief Medical & Marketing Officer
- Mr. Jim DennisonSenior VP and Chief Quality & Regulatory Affairs Officer
- Mr. John M. DunnChief Product Development & Digital Officer
- Mr. Kazuharu TomariPresident & GM of Japan Region
- Mr. Johannes Hogseth-DieboldPresident & GM of APAC REGION